Diverse therapeutic potential of 3-hydroxy-4-pyranones and related compounds as kojic acid analogs
Abstract Kojic acid (KA) is a natural product containing 3-hydroxy-4-pyranone scaffold. It is produced by various aerobic microorganisms such as Aspergillus and Penicillium species. Since this bioactive compound can inhibit tyrosinase enzyme, it has been mainly used as a whitening agent in cosmetics. KA is a polyfunctional heterocycle providing a potential intermediate for the design and synthesis of new biologically active compounds. Numerous studies demonstrated that KA-derived compounds have significant antibacterial, antifungal, anticancer, anticonvulsant, anti-Alzheimer’s disease and metal chelating activities. In this review, we have described diverse therapeutic potential of 3-hydroxy-4-pyranones and related compounds as kojic acid analogs. Modification of the natural product kojic acid has been considered for new lead generation with diverse biological activities..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Medicinal chemistry research - 31(2022), 11 vom: 05. Sept., Seite 1842-1861 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emami, Saeed [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
4-Pyranone |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00044-022-02954-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR048206474 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048206474 | ||
| 003 | DE-627 | ||
| 005 | 20230519134501.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220927s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00044-022-02954-3 |2 doi | |
| 035 | |a (DE-627)SPR048206474 | ||
| 035 | |a (SPR)s00044-022-02954-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Emami, Saeed |e verfasserin |0 (orcid)0000-0003-1665-6621 |4 aut | |
| 245 | 1 | 0 | |a Diverse therapeutic potential of 3-hydroxy-4-pyranones and related compounds as kojic acid analogs |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Kojic acid (KA) is a natural product containing 3-hydroxy-4-pyranone scaffold. It is produced by various aerobic microorganisms such as Aspergillus and Penicillium species. Since this bioactive compound can inhibit tyrosinase enzyme, it has been mainly used as a whitening agent in cosmetics. KA is a polyfunctional heterocycle providing a potential intermediate for the design and synthesis of new biologically active compounds. Numerous studies demonstrated that KA-derived compounds have significant antibacterial, antifungal, anticancer, anticonvulsant, anti-Alzheimer’s disease and metal chelating activities. In this review, we have described diverse therapeutic potential of 3-hydroxy-4-pyranones and related compounds as kojic acid analogs. Modification of the natural product kojic acid has been considered for new lead generation with diverse biological activities. | ||
| 650 | 4 | |a Kojic acid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a 4-Pyranone |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bioactive compounds |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug design |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lead generation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ahmadi, Reza |4 aut | |
| 700 | 1 | |a Ahadi, Hamideh |4 aut | |
| 700 | 1 | |a Ashooriha, Morteza |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicinal chemistry research |d Cambridge, Mass. [u.a.] : Birkhäuser Boston, 1991 |g 31(2022), 11 vom: 05. Sept., Seite 1842-1861 |w (DE-627)SPR000381640 |w (DE-600)2191978-1 |x 1554-8120 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2022 |g number:11 |g day:05 |g month:09 |g pages:1842-1861 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00044-022-02954-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2022 |e 11 |b 05 |c 09 |h 1842-1861 | ||